Background: Cancer immunotherapy treatments enhance the cancer treatment approach.
Theneutrophil-to-lymphocyteratio(NLR) has beenassociated with cancer
prognosis, affecting progression,chemosensitivity, radiosensitivity and toxicity. Patients
and Methods: Ten patients (nine males, one female), aged 68±10 years, were included in this study.Six patients hadsquamous cell carcinoma of
the lungs andtwo had
adenocarcinoma of the lungs. One patient suffered from limb soft tissue sarcoma
and one hadrenal
cell carcinoma. All patients had metastatic disease and were pretreated with
chemotherapy or biologic agents.The rationale of testing NLR was to compare it to
the clinical response of the patients assessed by RECIST criteria using
computerized tomography (CT) scans. Results: In regression analysis,
older patients were found to respond better to immunotherapy treatment than
youngerpatients. NLR was4.26
References
[1]
Pasquali, S., Chiarion-Sileni, V., Rossi, C.R. and Mocellin, S. (2017) Immune Checkpoint Inhibitors and Targeted Therapies for Metastatic Melanoma: A Network Meta-Analysis. Cancer Treatment Reviews, 54, 34-42.
https://doi.org/10.1016/j.ctrv.2017.01.006
[2]
de Mello, R.A., Veloso, A.F., Esrom Catarina, P., Nadine, S. and Antoniou, G. (2016) Potential Role of Immunotherapy in Advanced Non-Small-Cell Lung Cancer. OncoTargets and Therapy, 10, 21-30. https://doi.org/10.2147/OTT.S90459
[3]
Madureira, P., de Mello, R.A., de Vasconcelos, A. and Zhang, Y. (2015) Immunotherapy for Lung Cancer: For Whom the Bell Tolls? Tumor Biology, 36, 1411-1422.
https://doi.org/10.1007/s13277-015-3285-6
[4]
Ernst, B. and Anderson, K.S. (2015) Immunotherapy for the Treatment of Breast Cancer. Current Oncology Reports, 17, 5.
https://doi.org/10.1007/s11912-014-0426-9
[5]
Page, D.B., Bourla, A.B., Daniyan, A., Naidoo, J., Smith, E., Smith, M., et al. (2015) Tumor Immunology and Cancer Immunotherapy: Summary of the 2014 SITC Primer. Journal for ImmunoTherapy of Cancer, 3, 25.
https://doi.org/10.1186/s40425-015-0072-2
[6]
Vesely, M.D., Kershaw, M.H., Schreiber, R.D. and Smyth, M.J. (2011) Natural Innate and Adaptive Immunity to Cancer. Annual Review of Immunology, 29, 235-271. https://doi.org/10.1146/annurev-immunol-031210-101324
[7]
Ang, Y.L.E., Tan, H.-L. and Soo, R.A. (2015) Best Practice in the Treatment of Advanced Squamous Cell Lung Cancer. Therapeutic Advances in Respiratory Disease, 9, 224-235. https://doi.org/10.1177/1753465815581147
[8]
Rizvi, N.A., Mazières, J., Planchard, D., Stinchcombe, T.E., Dy, G.K., Antonia, S.J., et al. (2015) Activity and Safety of Nivolumab, an Anti-PD-1 Immune Checkpoint Inhibitor, for Patients with Advanced, Refractory Squamous Non-Small-Cell Lung Cancer (CheckMate 063): A Phase 2, Single-Arm Trial. The Lancet Oncology, 16, 257-265. https://doi.org/10.1016/S1470-2045(15)70054-9
[9]
Yaqub, F. (2015) Nivolumab for Squamous-Cell Non-Small-Cell Lung Cancer. The Lancet Oncology, 16, e319. https://doi.org/10.1016/S1470-2045(15)00033-9
[10]
Rounds, A. and Kolesar, J. (2015) Nivolumab for Second-Line Treatment of Metastatic Squamous Non-Small-Cell Lung Cancer. American Journal of Health-System Pharmacy, 72, 1851-1855. https://doi.org/10.2146/ajhp150235
[11]
Li, J., Chen, Q., Luo, X., Hong, J., Pan, K., Lin, X., Liu, X., Zhou, L., Wang, H., Xu, Y., Li, H. and Duan, C. (2015) Neutrophil-to-Lymphocyte Ratio Positively Correlates to Age in Healthy Population. Journal of Clinical Laboratory Analysis, 29, 437-443. https://doi.org/10.1002/jcla.21791
[12]
Buisan, O., Orsola, A., Areal, J., Font, A., Oliveira, M., Martinez, R. and Ibarz, L. (2017) Low Pretreatment Neutrophil-to-Lymphocyte Ratio Predicts for Good Outcomes in Patients Receiving Neoadjuvant Chemotherapy before Radical Cystectomy for Muscle Invasive Bladder Cancer. Clinical Genitourinary Cancer, 15, 145-151.e2.
https://doi.org/10.1016/j.clgc.2016.05.004
[13]
Boissier, R., Campagna, J., Branger, N., Karsenty, G. and Lechevallier, E. (2017) The Prognostic Value of the Neutrophil-Lymphocyte Ratio in Renal Oncology: A Review. Urologic Oncology, 35, 135-141. https://doi.org/10.1016/j.urolonc.2017.01.016
[14]
Personeni, N., Giordano, L., Abbadessa, G., Porta, C., Borbath, I., Daniele, B., et al. (2017) Prognostic Value of the Neutrophil-to-Lymphocyte Ratio in the ARQ 197-215 Second-Line Study for Advanced Hepatocellular Carcinoma. Oncotarget, 8, 14408-14415. https://doi.org/10.18632/oncotarget.14797
[15]
Shaverdian, N., Veruttipong, D., Wang, J., Schaue, D., Kupelian, P. and Lee, P. (2016) Pretreatment Immune Parameters Predict for Overall Survival and Toxicity in Early-Stage Non-Small-Cell Lung Cancer Patients Treated with Stereotactic Body Radiation Therapy. Clinical Lung Cancer, 17, 39-46.
https://doi.org/10.1016/j.cllc.2015.07.007
[16]
Bagley, S.J., Kothari, S., Aggarwal, C., Bauml, J.M., Alley, E.W., Evans, T.L., et al. (2017) Pretreatment Neutrophil-to-Lymphocyte Ratio as a Marker of Outcomes in Nivolumab-Treated Patients with Advanced Non-Small-Cell Lung Cancer. Lung Cancer, 106, 1-7. https://doi.org/10.1016/j.lungcan.2017.01.013
[17]
Nakamura, Y., Kitano, S., Takahashi, A., Tsutsumida, A., Namikawa, K., Tanese, K., et al. (2016) Nivolumab for Advanced Melanoma: Pretreatment Prognostic Factors and Early Outcome Markers during Therapy. Oncotarget, 7, 77404-77415.
https://doi.org/10.18632/oncotarget.12677
[18]
Feinberg, B.A., Bharmal, M., Klink, A.J., Nabhan, C. and Phatak, H. (2018) Using Response Evaluation Criteria in Solid Tumors in Real-World Evidence Cancer Research. Future Oncology. https://doi.org/10.2217/fon-2018-0317
[19]
Templeton, A.J., Knox, J.J., Lin, X., Simantov, R., Xie, W., Lawrence, N., et al. (2016) Change in Neutrophil-to-Lymphocyte Ratio in Response to Targeted Therapy for Metastatic Renal Cell Carcinoma as a Prognosticator and Biomarker of Efficacy. European Urology, 70, 358-364. https://doi.org/10.1016/j.eururo.2016.02.033
[20]
Chen, J., Hong, D., Zhai, Y. and Shen, P. (2015) Meta-Analysis of Associations between Neutrophil-to-Lymphocyte Ratio and Prognosis of Gastric Cancer. World Journal of Surgical Oncology, 13, 122. https://doi.org/10.1186/s12957-015-0530-9
